For 2-year survivors, patients with PTCL, NOS had a worse prognosis, with a COS3 rate of 67% compared with those with ALK+ALCL (95%), NK/TCL (88%), and ALK-ALCL (85%, Supplementary Table 2). Here, ALK is linked to anaplastic large cell lymphoma.